Strategic Global Advisors LLC Acquires 4,156 Shares of Bristol-Myers Squibb (NYSE:BMY)

Strategic Global Advisors LLC boosted its holdings in Bristol-Myers Squibb (NYSE:BMY) by 4.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 100,816 shares of the biopharmaceutical company’s stock after purchasing an additional 4,156 shares during the quarter. Bristol-Myers Squibb comprises 1.0% of Strategic Global Advisors LLC’s holdings, making the stock its 27th largest holding. Strategic Global Advisors LLC’s holdings in Bristol-Myers Squibb were worth $5,702,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in BMY. Burney Co. increased its holdings in Bristol-Myers Squibb by 4.2% in the fourth quarter. Burney Co. now owns 12,753 shares of the biopharmaceutical company’s stock worth $721,000 after purchasing an additional 516 shares in the last quarter. Carnegie Investment Counsel increased its holdings in shares of Bristol-Myers Squibb by 3.7% during the fourth quarter. Carnegie Investment Counsel now owns 33,435 shares of the biopharmaceutical company’s stock valued at $1,891,000 after acquiring an additional 1,193 shares in the last quarter. Ritholtz Wealth Management increased its holdings in shares of Bristol-Myers Squibb by 65.2% during the fourth quarter. Ritholtz Wealth Management now owns 39,389 shares of the biopharmaceutical company’s stock valued at $2,228,000 after acquiring an additional 15,546 shares in the last quarter. Goldstone Financial Group LLC increased its holdings in shares of Bristol-Myers Squibb by 6.1% during the fourth quarter. Goldstone Financial Group LLC now owns 4,824 shares of the biopharmaceutical company’s stock valued at $273,000 after acquiring an additional 279 shares in the last quarter. Finally, Procyon Advisors LLC increased its holdings in shares of Bristol-Myers Squibb by 8.3% during the fourth quarter. Procyon Advisors LLC now owns 18,660 shares of the biopharmaceutical company’s stock valued at $1,055,000 after acquiring an additional 1,423 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors.

Bristol-Myers Squibb Stock Performance

Shares of BMY opened at $46.77 on Friday. The firm has a market cap of $95.18 billion, a PE ratio of -10.58, a PEG ratio of 2.07 and a beta of 0.39. The stock’s fifty day moving average price is $53.05 and its two-hundred day moving average price is $55.99. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.25 and a quick ratio of 1.15. Bristol-Myers Squibb has a 1 year low of $39.35 and a 1 year high of $63.33.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.50 by $0.30. The firm had revenue of $11.20 billion for the quarter, compared to analyst estimates of $10.77 billion. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. The business’s revenue was down 5.6% on a year-over-year basis. During the same period in the previous year, the company posted ($4.40) earnings per share. On average, equities research analysts forecast that Bristol-Myers Squibb will post 6.74 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, May 1st. Shareholders of record on Friday, April 4th were paid a $0.62 dividend. The ex-dividend date of this dividend was Friday, April 4th. This represents a $2.48 annualized dividend and a dividend yield of 5.30%. Bristol-Myers Squibb’s payout ratio is presently 92.88%.

Insider Buying and Selling at Bristol-Myers Squibb

In other news, EVP Samit Hirawat bought 4,250 shares of the stock in a transaction on Friday, April 25th. The shares were purchased at an average cost of $47.58 per share, for a total transaction of $202,215.00. Following the completion of the purchase, the executive vice president now directly owns 83,513 shares in the company, valued at $3,973,548.54. This represents a 5.36% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 0.09% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on BMY shares. William Blair restated a “market perform” rating on shares of Bristol-Myers Squibb in a report on Friday, April 25th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $55.00 target price (down previously from $67.00) on shares of Bristol-Myers Squibb in a research report on Tuesday, April 8th. Jefferies Financial Group cut their target price on Bristol-Myers Squibb from $70.00 to $68.00 and set a “buy” rating on the stock in a research report on Wednesday, April 23rd. UBS Group cut their target price on Bristol-Myers Squibb from $60.00 to $54.00 and set a “neutral” rating on the stock in a research report on Friday, April 11th. Finally, Citigroup lifted their target price on Bristol-Myers Squibb from $60.00 to $65.00 and gave the company a “neutral” rating in a research report on Tuesday, January 28th. Two research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have given a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Bristol-Myers Squibb has an average rating of “Hold” and an average target price of $58.00.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.